Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation ...

Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation ...

Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway. The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC ...

Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.